Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peer B Jacobson

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Neurobiology of Disease|May 15, 2021
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primatesPeer B Jacobson, Robin Goody, Matthew Lawrence, et al.
Journal of Medicinal Chemistry|August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetesThomas W von Geldern, Noah Tu, Philip R Kym, et al.
Journal of Medicinal Chemistry|March 7, 2003
Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolinesPhilip R Kym, Michael E Kort, Michael J Coghlan, et al.
Journal of Medicinal Chemistry|April 14, 2006
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonistsMichael D Serby, Hongyu Zhao, Bruce G Szczepankiewicz, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Journal of Medicinal Chemistry|July 21, 2006
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonistsZhili Xin, Michael D Serby, Hongyu Zhao, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitorsJeffrey J Rohde, Marina A Pliushchev, Bryan K Sorensen, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Neurobiology of Disease|May 15, 2021
Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primatesPeer B Jacobson, Robin Goody, Matthew Lawrence, et al.
Journal of Medicinal Chemistry|August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetesThomas W von Geldern, Noah Tu, Philip R Kym, et al.
Journal of Medicinal Chemistry|March 7, 2003
Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolinesPhilip R Kym, Michael E Kort, Michael J Coghlan, et al.
Journal of Medicinal Chemistry|April 14, 2006
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonistsMichael D Serby, Hongyu Zhao, Bruce G Szczepankiewicz, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Journal of Medicinal Chemistry|July 21, 2006
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonistsZhili Xin, Michael D Serby, Hongyu Zhao, et al.
Journal of Medicinal Chemistry|January 5, 2007
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitorsJeffrey J Rohde, Marina A Pliushchev, Bryan K Sorensen, et al.
Pageof 3